Poland's Bladder Cancer Fight: Modern Medicine Outpaces Treatment Access

Bladder cancer continues to be a formidable foe in Poland, a fact underscored by its insidious nature and its significant impact on male mortality rates. The challenge is not merely the disease itself, but the systemic delays in diagnosis and treatment that plague our healthcare system. Blood in the urine, the most critical warning sign, is too often overlooked by both patients and medical professionals, leading to precious time lost in the fight against a cancer that is fully curable in its early stages.

Experts rightly emphasize the need for "oncological vigilance" among primary care physicians and the public. A clear message must resonate: any instance of blood in the urine demands immediate medical attention. While preventative measures are vital, especially for at-risk groups like men over 60, smokers, or those exposed to chemicals, the diagnostic pathway remains a bottleneck. Discussions about removing referral requirements to urologists are ongoing, but without strengthening the role of general practitioners, this could create new inefficiencies. Better utilization of existing tools like the DiLO (cancer diagnostic pathway) and enhanced medical staff education are essential steps forward.

Furthermore, the advent of modern therapies such as immunotherapy and targeted drugs has revolutionized bladder cancer treatment globally, offering significantly improved outcomes even for advanced cases. Combined therapies, like enfortumab vedotin with pembrolizumab, show remarkable promise in extending patient lives. However, the reality in Poland is a stark contrast. Access to these life-saving treatments remains restricted. According to the Alivia Oncoindex project, Polish patients currently have only 50% access to therapies recommended by the European Society for Clinical Oncology, a figure that highlights a critical gap between global advancements and local availability. This disparity is a grave concern for the future of cancer care in our country.

“

Oncofundacja Alivia prowadzi projekt Alivia Oncoindex, gdzie badamy dostępność do terapii, które zostały zarejestrowane przez Europejską Agencję Leków w ciągu ostatnich 19 lat i są rekomendowane przez ESMO, czyli Europejskie Towarzystwo Onkologii Klinicznej. Aktualnie wskaźnik ten w Polsce, dla raka pęcherza moczowego, wynosi 50 punktów w skali do 100. Oznacza to, że pacjenci w naszym kraju mają tylko częściowy dostęp do terapii